• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Monopar Therapeutics Inc.

    6/2/23 4:57:21 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNPR alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. __)*

     

    Monopar Therapeutics Inc.

     

    (Name of Issuer)

     

    Common Stock

     

    (Title of Class of Securities)

     

    61023L108

     

    (CUSIP Number)

     

    May 26, 2023

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1 (b)

    ☒ Rule 13d-1 (c)

    ☐ Rule 13d-1 (d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     

     

     

     

     

    CUSIP No. 61023L108 13G Page 2 of 5 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Jeffrey Klunzinger

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  

    (a) ☐

    (b) ☒  

    3

    SEC USE ONLY  

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY

    OWNED BY
    EACH
    REPORTING
    PERSON
    5

    SOLE VOTING POWER

    692,800

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    692,800

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    692,800

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.24%*

    12

    TYPE OF REPORTING PERSON

    IN

     

    * Based on 13,222,056 shares outstanding as of April 28, 2023 as reported in the Subject Company’s Quarterly Report on Form 10-Q filed on May 11, 2023.

     

     

     

     

    CUSIP No. 61023L108 13G Page 3 of 5 Pages

     

    Item 1(a). Name of Issuer: Monopar Therapeutics Inc.
       
    Item 1(b). Address of Issuer’s Principal Executive Offices: 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.
       
    Item 2(a). The names of persons filing this statement: Jeffrey Klunzinger.
       
    Item 2(b). The principal business office of the Filers is located at: 310 Busse Hwy, Suite 490, Park Ridge, IL 60068.
       
    Item 2(c). For citizenship of Filers, see Item 4 of the cover sheet for each Filer.
       
    Item 2(d). This statement relates to shares of Common Stock of the Issuer (the “Stock”).
       
    Item 2(e). CUSIP Number: 61023L108
       
    Item 3. If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      e) ☐ An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E).
           
      f) ☐ An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).
           
      g) ☐ A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)
           
      h) ☐ A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
           
      i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
           
      j) ☐ A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).
           
      k) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution ________________________________________________________.

     

     

     

     

    CUSIP No. 61023L108 13G Page 4 of 5 Pages

     

    Item 4. Ownership:

     

    (a) Amount Beneficially Owned: 692,800 shares.

     

    (b) Percent of Class: 5.24%, based on 13,222,056 shares outstanding as of April 28, 2023 as reported in the Subject Company’s Quarterly Report on Form 10-Q filed on May 11, 2023.

     

    (c) Number of shares as to which such person has:

     

      (i) sole power to vote or to direct the vote: 692,800 shares.
         
      (ii) shared power to vote or to direct the vote: 0 shares.
         
      (iii) sole power to dispose or to direct the disposition of: 692,800 shares.
         
      (iv) shared power to dispose or to direct the disposition of: 0 shares.

     

    Item 5. Ownership of Five Percent or Less of a Class: Not Applicable
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person: Not Applicable
       
    Item 7. Identification and Classification of Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company: Not Applicable
       
    Item 8. Identification and Classification of Members of the Group: Not Applicable
       
    Item 9. Notice of Dissolution of Group: Not Applicable
       
    Item 10. Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No. 61023L108 13G Page 5 of 5 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      June 2, 2023
       
      /s/ Jeffrey Klunzinger
      Jeffrey Klunzinger

     

     

     

    Get the next $MNPR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MNPR

    DatePrice TargetRatingAnalyst
    7/7/2025$74.00Overweight
    Cantor Fitzgerald
    6/23/2025$60.00Buy
    Chardan Capital Markets
    3/19/2025$76.00Overweight
    Piper Sandler
    1/10/2025$72.00Overweight
    Piper Sandler
    10/11/2024$50.00Buy
    Rodman & Renshaw
    11/1/2021$9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $MNPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Tsuchimoto Kim R exercised 8,904 in-the-money shares at a strike of $0.01 and sold $356,171 worth of shares (8,904 units at $40.00) (SEC Form 4)

      4 - Monopar Therapeutics (0001645469) (Issuer)

      7/16/25 9:06:13 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Starr Christopher M exercised 16,800 in-the-money shares at a strike of $0.01 and sold $672,020 worth of shares (16,800 units at $40.00) (SEC Form 4)

      4 - Monopar Therapeutics (0001645469) (Issuer)

      7/16/25 9:03:50 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Robinson Chandler exercised 16,800 in-the-money shares at a strike of $0.01 and sold $672,020 worth of shares (16,800 units at $40.00) (SEC Form 4)

      4 - Monopar Therapeutics (0001645469) (Issuer)

      7/16/25 9:02:07 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Monopar Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $74.00

      7/7/25 8:21:17 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital Markets initiated coverage on Monopar Therapeutics with a new price target

      Chardan Capital Markets initiated coverage of Monopar Therapeutics with a rating of Buy and set a new price target of $60.00

      6/23/25 8:07:37 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler resumed coverage on Monopar Therapeutics with a new price target

      Piper Sandler resumed coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $76.00

      3/19/25 8:17:26 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Radhakrishnan Karthik bought $25,188 worth of shares (1,550 units at $16.25) (SEC Form 4)

      4 - Monopar Therapeutics (0001645469) (Issuer)

      10/30/24 4:17:28 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Cittadine Andrew bought $25,574 worth of shares (32,508 units at $0.79), increasing direct ownership by 21% to 186,132 units (SEC Form 4)

      4 - Monopar Therapeutics (0001645469) (Issuer)

      6/21/24 5:16:51 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Cittadine Andrew bought $32,894 worth of shares (36,000 units at $0.91), increasing direct ownership by 31% to 153,624 units (SEC Form 4)

      4 - Monopar Therapeutics (0001645469) (Issuer)

      6/17/24 6:08:20 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNPR
    SEC Filings

    See more
    • SEC Form 144 filed by Monopar Therapeutics Inc.

      144 - Monopar Therapeutics (0001645469) (Subject)

      7/14/25 12:29:46 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Monopar Therapeutics Inc.

      144 - Monopar Therapeutics (0001645469) (Subject)

      7/14/25 12:26:14 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Monopar Therapeutics Inc.

      DEFA14A - Monopar Therapeutics (0001645469) (Filer)

      5/23/25 3:48:33 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNPR
    Leadership Updates

    Live Leadership Updates

    See more
    • Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

      Monopar's pipeline includes clinical-stage radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease  NORTH CHICAGO, Ill., Jan. 23, 2025 /PRNewswire/ -- Rosalind Franklin University of Medicine and Science announced that Monopar Therapeutics is the latest biotech company to join the Helix 51 biomedical incubator community. Monopar, a clinical-stage biotechnology firm, is developing personalized and precise radiopharmaceuticals to diagnose and treat aggressive cancers, and will utilize the labs and other resources in Helix 51 t

      1/23/25 1:10:00 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Monopar Appoints Octávio Costa, MD, as Chief Medical Officer

      WILMETTE, Ill., July 12, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the appointment of Octávio Costa, MD, as Chief Medical Officer. In this role, Dr. Costa will oversee global clinical development and regulatory affairs, and will provide strategic direction for Monopar's pipeline. Dr. Costa joins Monopar with over 30 years of experience overseeing clinical development, clinical operations, development strategy and global medical affairs. He has extensive Phase 1 through 4 clini

      7/12/21 8:00:00 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Monopar Therapeutics Expands Leadership Team with Appointment of Andrew Cittadine as Chief Operating Officer

      WILMETTE, Ill., June 01, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the appointment of Andrew Cittadine, MBA, as Chief Operating Officer. In this role, Mr. Cittadine will provide leadership and oversight of Monopar's global operations and business and development strategy. Mr. Cittadine is an experienced healthcare executive and serial entrepreneur with a successful track record of identifying, founding, and building healthcare businesses from concept to commercialization

      6/1/21 4:05:00 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

      WILMETTE, Ill. and HOUSTON, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar," the "Company," "us" and "our") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, in collaboration with Excel Diagnostics and Nuclear Oncology Center ("EDNOC"), a premier diagnostic medical imaging and therapeutic nuclear medicine center, today announced that the physician-sponsored Expanded Access Program ("EAP") for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu has received authorization to proceed from the U.S. Food and Drug Administration ("FD

      6/11/25 7:00:00 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

      WILMETTE, Ill., June 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that it will be added to the broad-market Russell 3000® Index, with automatic inclusion in the small-cap Russell 2000® Index, after the close of U.S. equity markets on June 27, 2025. The inclusion follows the initial announcement on Friday, May 23, and the subsequent update on Friday, May 30, 2025, in connection with the annual reconstitution of the Russell U.S. Indexes. The Russell 2000® Index tracks the performance of the small-c

      6/3/25 7:00:00 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

      WILMETTE, Illinois, May 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced first quarter 2025 financial results and recent developments. Recent Developments ALXN1840 for Wilson Disease On May 7, 2025, Monopar presented long-term efficacy and safety data for ALXN1840 (tiomolybdate choline) at the European Association for the Study of the Liver ("EASL") International Liver Congress 2025, a leading global conference in liver disease. The data support ALXN1840 as a potential treatment for Wilson disease

      5/13/25 8:00:00 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

      SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

      12/17/24 5:01:42 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Monopar Therapeutics Inc.

      SC 13G - Monopar Therapeutics (0001645469) (Subject)

      11/6/24 3:13:14 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Monopar Therapeutics Inc.

      SC 13G - Monopar Therapeutics (0001645469) (Subject)

      10/31/24 4:17:57 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNPR
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

      Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

      6/22/24 8:00:00 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care